European Pharmaceutical Review

NOVEMBER 7, 2023

Positive results for a combination treatment using the first Fc-silent investigational monoclonal antibody in pivotal clinical trials that is designed to block and bind to the T-cell immunoreceptor with Ig and ITIM domains (TIGIT), have been announced. The treatment is being evaluated in patients with upper GI adenocarcinomas.

Safety 95

Safety Patients Physicians Medical 95

Pharmaceutical Technology

JUNE 10, 2023

Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Metastatic Lung Cancer. According to GlobalData, Phase I drugs for Metastatic Lung Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. It is a small molecule administered orally.

Food and Drug Administration 40

Food and Drug Administration Pharmaceutical Food Manufacturing 40

Pharmaceutical Technology

JUNE 10, 2023

Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Metastatic Lung Cancer. According to GlobalData, Phase I drugs for Metastatic Lung Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. It is a small molecule administered orally.

Food and Drug Administration 40

Food and Drug Administration Pharmaceutical Food Manufacturing 40

European Pharmaceutical Review

JULY 5, 2022

Stomach cancer, also known as gastric cancer, is the fifth most common type of cancer worldwide – and the third most common cause of death from cancer. Stomach cancer, also known as gastric cancer, is the fifth most common type of cancer worldwide – and the third most common cause of death from cancer.

Patients 86

Patients Food and Drug Administration Side effects Safety 86

European Pharmaceutical Review

JANUARY 23, 2023

For the first time, a clinical study in the first-line setting for mPDAC demonstrated superior overall survival (OS) and progression-free survival (PFS) for an investigational regimen when compared to standard of care treatment with nab-paclitaxel and gemcitabine.”

Food and Drug Administration 87

Food and Drug Administration Medicine Patients Food 87

European Pharmaceutical Review

NOVEMBER 17, 2022

In pre-clinical studies, this binding interaction caused cancer cell death by activating antibody-dependent cellular toxicity and complement-dependent cytotoxicity immune system pathways. Gastric and GEJ cancers still have very limited treatment options available for patients with an advanced diagnosis.”. expression in ? “I

Safety 78

Safety Patients Pharma Pharmaceutical 78

Pharmaceutical Technology

FEBRUARY 23, 2023

Buparlisib hydrochloride is under clinical development by Adlai Nortye Biopharma and currently in Phase II for Mantle Cell Lymphoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Biopharma 52

Biopharma Pharmaceutical 52

European Pharmaceutical Review

NOVEMBER 4, 2022

Despite advances with targeted and immuno-oncology therapies, chemotherapies remain a cornerstone of cancer treatment for many tumour types – a reflection of their significant anti?tumour They are widely used to treat a variety of solid tumours, including prostate, lung, ovarian and breast cancer. tumour effects.

Food and Drug Administration 84

Food and Drug Administration FDA Pharmaceutical Patients 84

pharmaphorum

AUGUST 2, 2022

AbbVie and Sosei Heptares will initially focus on developing up to three GPCR-modulating small-molecule drugs to the point at which they are ready to start clinical trials in humans, whereupon AbbVie has opt-in rights to take them further. The new agreement follows earlier alliances including one worth up to $2.6

Pharma 75

Pharma Marketing Medicine 75

Pharmaceutical Technology

JUNE 27, 2022

Turning Point Therapeutics has entered a strategic research and development alliance with the University of Texas MD Anderson Cancer Center (MD Anderson) to advance the evaluation of two of its investigational small molecules for precision cancer treatments. A kinase inhibitor, elzovantinib (TPX-0022) targets MET, CSF1R and SRC.

Patients 59

Patients Leads Medical Pharmaceutical 59

European Pharmaceutical Review

MARCH 4, 2024

This growth is accompanied by a substantial number of clinical trials, with close to 20,000 active investigations, involving about 9,500 new biologic treatments. These actions occur at both the delivery site and other systemic locations, thereby promoting an immunogenic response that leads to cancer cell death. percent through 2027.

Food and Drug Administration 91

Food and Drug Administration Transportation FDA Medical 91

Pharmaceutical Technology

APRIL 24, 2023

As healthcare confronts challenges such as antimicrobial resistance and the spread of previously geographically constrained diseases as a result of climate change, research into natural products used in traditional medicine, referred to as ‘ethnopharmacology’, could help in finding new, clinically effective drugs.

Medicine 105

Medicine Side effects Healthcare Healthcare 105

Legacy MEDSearch

FEBRUARY 21, 2023

Use of the C¹ and grasper helps improve curativeremoval of precancerous and non-invasive cancerous polyps during ESD. Lumendi focuses on developing, marketing and distributing surgical tools and devices that provide safe, cost-effective solutions for minimally invasive gastrointestinal interventions.

Food and Drug Administration 98

Food and Drug Administration Recruitment Medical Distribution 98

Pharmaceutical Technology

MAY 31, 2023

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III.

Pharmaceutical 40

Pharmaceutical Retail Networking Marketing 40

Pharmaceutical Technology

APRIL 12, 2023

The latest move is a result of the cancellation of a licensing agreement between Cancer Prevention Pharmaceuticals (CPP) and One-Two Therapeutics Assets. It is expected to focus on FAP patients with intact lower gastrointestinal anatomy. The new registration trial will be based on positive data obtained from the FAP-310 trial.

Patients 52

Patients Safety Medicine FDA 52

pharmaphorum

JUNE 23, 2022

BRAF V600E mutations are seen in around 20 different types of cancer, said Novartis, which has previously won regulatory approvals for the combination as treatment for BRAF-mutated melanoma, non-small cell lung cancer (NSCLC) and thyroid cancers. billion to Novartis’ top-line last year. Tabrecta approved in Europe.

FDA 52

FDA Sales Patients Leads 52

Medgadget

MAY 10, 2023

The researchers hope that the device could assist patients with eating disorders or conditions such as cachexia, a wasting condition that can occur in cancer patients. They tested their hypothesis in animals, finding that a small electrical current in the stomach did indeed increase ghrelin levels.

Patients 86

Patients Management 86

Pharmaceutical Technology

FEBRUARY 19, 2023

Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Medicine 40

Medicine Distribution Pharmaceutical products Networking 40

Pharma Marketing Network

MARCH 2, 2022

” IQVIA measures its success of novel molecules in clinical trials by clinical development productivity, which experienced a decline across all disease areas in 2021, except for, of course, vaccines and in cardiovascular. 3 therapeutic areas with the most growth are oncology, gastrointestinal disorders, and neurology.

52

52

Pharmaceutical Technology

MARCH 2, 2023

Rituximab biosimilar is under clinical development by Dr. Reddy’s Laboratories and currently in Phase III for Rheumatoid Arthritis. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company also develops and markets generic biosimilar products.

Pharmaceutical 40

Pharmaceutical Marketing Manufacturing 40

Pharma Marketing Network

MARCH 2, 2022

” IQVIA measures its success of novel molecules in clinical trials by clinical development productivity, which experienced a decline across all disease areas in 2021, except for, of course, vaccines and in cardiovascular. 3 therapeutic areas with the most growth are oncology, gastrointestinal disorders, and neurology.

Networking 52

Networking Pharma Marketing 52

Legacy MEDSearch

MAY 24, 2022

The C¹ and Grasper will improve enbloc dissection of precancerous and non-invasive cancerous polyps, a procedure known as Endoscopic Submucosal Dissection (ESD). C¹’s design offers a single working channel that accommodates an atraumatic grasper, which provides more direct tissue manipulation and traction. Press Release by: Lumendi, LLC.

Food and Drug Administration 52

Food and Drug Administration FDA Recruitment Food 52

European Pharmaceutical Review

MARCH 24, 2023

He also shares key data from the ongoing Phase IIb clinical trial, and discusses the broader challenges of developing novel therapies in the NASH space. Data from clinical trials to-date suggests that pegozafermin could reduce hepatic fat and fibrosis. How does pegozafermin work in potentially treating NASH?

Medical 86

Medical Side effects Safety Pharmaceutical 86

Pharmaceutical Technology

APRIL 14, 2023

Madrigal Pharmaceuticals’ resmetirom for nonalcoholic steohepatitis (NASH) could be fairly priced at a higher range than Intercept Pharmaceuticals’ obeticholic acid, based on a revised evidence report published by the Institute for Clinical and Economic Review (ICER).

Side effects 52

Side effects Patients Leads Pharmaceutical 52

Evolve Your Success

SEPTEMBER 5, 2023

For this Special Labor Day episode, we’re going to dive into the cutting-edge world of AI revolutionizing healthcare, specifically in the field of gastrointestinal medicine. He showcases prowess in sales, marketing, clinical training, and serving as a product specialist. Tune in now and discover a new horizon of patient care.

Medical 52

Medical Medical sales Doctors Sales 52

Medico Reach

OCTOBER 10, 2022

The categories for these instruments include: Cardiovascular Digestive and gastrointestinal Spinal and Orthopedic Diabetes Ear, nose, and throat Urological and urogynecological Patient care Surgery Respiratory Neurological. It provides injectable medications and infusion technology.

Manufacturing 98

Manufacturing Medical Education Specialization 98

European Pharmaceutical Review

APRIL 10, 2024

Engaging in continuous dialogue with regulatory bodies in Europe and the US helps in designing clinical trials that follow the latest safety standards and international regulations. During the development of clinical trials that use faecal-derived material, the necessity of safety is paramount.

Safety 85

Safety Patients Medical FDA 85

pharmaphorum

NOVEMBER 29, 2022

Number of on-going clinical trials: 14. By enabling strong CD8 T-cell infiltration in cold tumor tissues, NT-I7, a compound developed by NeoImmuneTech, is capable of promoting a microenvironment that contributes to clinical efficacy, when combined with a CPI. Locations: 3 (US HQ, Korea office, Korea R&D center). Creation: Jan.

Safety 105

Safety Patients Engineering Recruitment 105

PM360

MAY 16, 2023

McCourt has been in the industry for more than 35 years with most of that time spent contributing to some of the biggest breakthroughs within the gastrointestinal (GI) space. This year that honor goes to Tom McCourt, CEO, Ironwood Pharmaceuticals. 1 GI company in the U.S.

Media 52

Media Marketing Management Pharmaceutical 52

European Pharmaceutical Review

OCTOBER 19, 2023

The development of novel radiotherapeutics ushered in a new era in targeted treatment 1 for cancer, with two separate radiotherapeutic approvals in Europe and the US, in 2018 and 2022. The introduction of large-scale Phase III clinical trials with control arms has had a major impact on the radiopharmaceutical landscape.

Food and Drug Administration 91

Food and Drug Administration Side effects Manufacturing Doctors 91

Pharmaceutical Technology

FEBRUARY 26, 2023

This is largely due to the FDA’s rigorous approach to the safety of microbiome therapeutics, which has manifested in clinical holds, resulting in delays that have dimmed the enthusiasm in the space in recent times. The potential use of microbiome therapeutics in cancer comes with its own set of questions.

Safety 111

Safety FDA Medicine Side effects 111

Pharmaceutical Technology

JANUARY 4, 2023

Ondansetron hydrochloride CR is under clinical development by RedHill Biopharma and currently in the Phase II and Phase III in clinical pathway. RedHill Biopharma overview RedHill Biopharma (RedHill) is a specialty biopharmaceutical company that develops and commercializes therapeutics for gastrointestinal (GI) diseases and cancer.

Biopharma 40

Biopharma Prescription Pharmaceutical 40

Pharmaceutical Technology

MARCH 2, 2023

Pembrolizumab is under clinical development by Merck and currently in Phase III for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase III drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.

Patients 40

Patients FDA Prescription Retail 40

Pharmaceutical Technology

FEBRUARY 24, 2023

cell surface protein, including gastric cancers. Currently, the ADC is being assessed in a Phase I clinical trial to treat Claudin 18.2-positive positive solid tumours, including gastric cancer. expressing cancers. It is being developed to treat solid tumours that express the Claudin 18.2

Biopharma 52

Biopharma Engineering Pharmaceutical Safety 52